DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis. Future Oncol. 2021 Aug 31. doi: 10.2217/fon-2021-0742.


AIM: A systematic literature review and network meta-analysis of randomized controlled trials in HER2+ unresectable or metastatic breast cancer was conducted to compare progression-free survival (PFS) and overall survival (OS).

METHODS: Hazard ratios (HRs) and relative differences from fractional polynomials (FPs) for PFS and OS were assessed by Bayesian network meta-analyses.

RESULTS: For PFS, surface under the cumulative rankogram (SUCRA) ranked tucatinib combination highest in both HR and FP analyses, followed by T-DM1 monotherapy and neratinib plus capecitabine. For OS, SUCRA ranked tucatinib combination highest in both HR and FP analyses, followed by the pertuzumab combination and T-DM1, with similar scores.

CONCLUSION: Tucatinib combination and T-DM1 monotherapy consistently showed improved PFS and OS versus lapatinib/trastuzumab plus capecitabine and non-targeted treatments.

Share on: